Streetbeat News

Price Targets

LLY

Goldman Sachs predicts a 140% surge in Eli Lilly and Co. (NYSE:LLY) shares due to the booming demand for GLP-1 weight loss and diabetes drugs. The bank estimates that by 2028, GLP-1 drugs like Eli Lilly's Mounjaro and Zepbound could be used by 68 million Americans, potentially generating $400 billion in revenue. Despite this, Goldman Sachs maintains a 'Neutral' rating on Eli Lilly with a $600 price target, a 5% upside from current levels. The bank highlights the importance of upcoming GLP-1 studies which could further drive demand.

Portfolio Pulse from Benzinga Neuro

December 19, 2023 | 5:03 am

WELL

Welltower (NYSE:WELL) has received updated ratings and price targets from 9 financial analysts in the last quarter. The average 12-month price target is $93.22, with a high of $101.00 and a low of $83.00. The ratings are mostly bullish or neutral, with 1 bullish, 4 somewhat bullish, and 4 indifferent. Notably, the average price target has increased by 3.91% over the past month. Welltower's financial health indicators show a strong market presence, positive revenue trend, but below-average net margin and ROE, with an exceptional ROA and a balanced debt approach.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:01 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) received 6 analyst ratings in the last quarter, with an average 12-month price target of $19.17, a decline of 11.54% from the prior average. Ratings include 2 bullish, 2 somewhat bullish, and 2 indifferent. Notable actions include Stifel's Alex Thompson lowering the price target from $2.00 to $1.00 and HC Wainwright & Co.'s Raghuram Selvaraju lowering from $43.00 to $9.00. Aclaris focuses on immuno-inflammatory diseases and earns most revenue from its contract research segment. It has a low market cap, a significant revenue decline of -51.19%, a high net margin of -315.24%, an ROE of -17.41%, an ROA of -12.89%, and no debt.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:01 pm

UTZ

Analysts have provided 11 recent ratings for Utz Brands (NYSE:UTZ), with an average price target of $16.18, down from $18.78. The ratings include 1 bullish, 7 somewhat bullish, and 3 indifferent. Notable analysts from firms like Piper Sandler, RBC Capital, and Goldman Sachs have adjusted their price targets and ratings, reflecting a mix of raised and lowered expectations. Utz Brands has shown a revenue growth rate of 2.49% as of September 30, 2023, a net margin of 4.3%, but a lower ROE of 2.29% and ROA of 0.57%, with a high debt-to-equity ratio of 1.42.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:01 pm

SYF

Synchrony Financial (NYSE:SYF) has been rated by 10 analysts in the last quarter with 2 bullish, 4 somewhat bullish, 2 indifferent, and 2 somewhat bearish ratings. The average 12-month price target is $35.2, down 4.56% from the previous $36.88. Analysts from firms like Goldman Sachs, JMP Securities, Piper Sandler, Morgan Stanley, JP Morgan, HSBC, and Citigroup have adjusted their price targets and ratings, reflecting their views on the company's market position and financial performance. Synchrony Financial has shown strong financial indicators such as a 19.21% revenue growth rate, a net margin of 17.78%, and a ROE of 4.81%.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

VSEC

Analysts have recently provided ratings for VSE Corporation (NASDAQ:VSEC), with 6 analysts offering a 12-month average price target of $75.33, a high estimate of $85.00, and a low estimate of $65.00. The average price target has increased by 11.88% over the past month. Analysts from Benchmark and Truist Securities have raised their price targets, while RBC Capital has both raised and maintained its targets. VSE's financials show strong revenue growth and net margin, but a lower than average Return on Equity (ROE).

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

REGN

Over the past 3 months, 14 Wall Street analysts have published their opinions on Regeneron Pharmaceuticals (NASDAQ:REGN), with an average 12-month price target of $920.0, a high of $1045.00, and a low of $800.00. The current average price target has increased by 4.74% from the previous average of $878.38. Analysts' ratings range from 'Buy' to 'Hold', with various actions taken including maintaining, raising, and lowering price targets. Regeneron is involved in developing treatments for various diseases and has several marketed products. Financially, the company shows strong performance with a high net margin and ROE, low debt-to-equity ratio, but a revenue growth rate lower than the Health Care sector average.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:00 pm

LUV

Southwest Airlines (NYSE:LUV) has received mixed analyst ratings in the last quarter, with 0 bullish, 3 somewhat bullish, 5 indifferent, 1 somewhat bearish, and 0 bearish. The average 12-month price target from 9 analysts is $29.33, down from the previous $32.11, indicating a negative sentiment shift. Analysts from firms like Citigroup, Raymond James, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Despite the mixed ratings, Southwest Airlines has shown strong financial indicators such as a 4.9% revenue growth rate, a net margin of 2.96%, an ROE of 1.77%, an ROA of 0.53%, and a low debt-to-equity ratio of 0.84.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 8:00 pm

MIRM

HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) but has reduced the price target from $60 to $58.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 7:34 pm

BIL

EWJ

EWU

HYG

IEF

IVV

JPM

SPY

TLT

USHY

UUP

VOO

JPMorgan Chase & Co (NYSE:JPM) predicts the S&P 500 will test the 5,000 level in 2024, recommending overweight positions in U.S. and Japanese equities, U.S. Treasury, and high-yield corporate debt. They suggest underweight positions in European equity and Emerging Markets (ex-China). JPMorgan expects U.S. equities to see broadened performance beyond tech, with an earnings growth estimate of 7% into the next year. They also see potential in Japanese stocks due to corporate governance reforms. In fixed-income, they recommend U.S. Treasuries and high-yield corporate debt, anticipating rate cuts in 2024. The US dollar is expected to weaken, and cash returns are set to fall.

Portfolio Pulse from Surbhi Jain

December 18, 2023 | 7:28 pm